Benign prostatic hyperplasia: Implications for pharmacologic treatment and perioperative care

Journal of Pharmacy Practice

Volumn 26, Issue 1, 2013, Pages 52-58

  Leedahl, David D ^a   Vo, Phil H ^a   Maxson, Pamela M ^a   Lovely, Jenna K ^a  

^a MAYO CLINIC   (United States)

Author keywords

perioperative care; postoperative complications; prostatic hyperplasia; surgery; urology

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ANDROSTANOLONE; DOXAZOSIN; DOXAZOSIN MESYLATE; DUTASTERIDE; FINASTERIDE; LOW MOLECULAR WEIGHT HEPARIN; PRAZOSIN; PROSTATE SPECIFIC ANTIGEN; SILODOSIN; TAMSULOSIN; TERAZOSIN; TOLTERODINE; WARFARIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; STEROID 5ALPHA REDUCTASE INHIBITOR;

ANTICOAGULANT THERAPY; BLADDER NECK STENOSIS; BLOOD PRESSURE MONITORING; BRAIN EDEMA; CONFUSION; DIGITAL RECTAL EXAMINATION; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; EJACULATION DISORDER; FATIGUE; HEADACHE; HOLMIUM LASER; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; LENGTH OF STAY; LOWER URINARY TRACT SYMPTOM; MALE; MINIMALLY INVASIVE SURGERY; NOCTURIA; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTVOID RESIDUAL URINE VOLUME; PROPHYLAXIS; PROSTATE; PROSTATE HYPERTROPHY; PROSTATE SIZE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROGRADE EJACULATION; REVIEW; RHINITIS; RISK REDUCTION; SEIZURE; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; SMOOTH MUSCLE TONE; STANDING; TESTOSTERONE BLOOD LEVEL; TRANSURETHRAL RESECTION; TREATMENT DURATION; TREATMENT OUTCOME; TWITCHING MOTILITY; URETHRAL BLEEDING; URGE INCONTINENCE; URINALYSIS; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; COMBINATION DRUG THERAPY; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROSTATIC HYPERPLASIA;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROSTATIC HYPERPLASIA;

EID: 84879439971     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190012451913     Document Type: Review

References (36)

1. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009 ; 36 (4). 403-415
2. Albertsen PC, Pellissier JM, Lowe FC, et al. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin Ther. 1999 ; 21 (6). 1006-1024 (Pubitemid 29326160)
3. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 ; 185 (5). 1793-1803
4. Ahyai SA, Gilling P, Kaplan SA, et al. Meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol. 2010 ; 58 (3). 384-397
5. Reynard JM. Does anticholinergic medication have a role for men with lower urinary tract symptoms/benign prostatic hyperplasia either alone or in combination with other agents?. Curr Opin Urol. 2004 ; 14 (1). 13-16 (Pubitemid 39186207)
6. Zhu YS. Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci. 2009 ; 1155: 43-56
7. Stoner E. The clinical development of a 5 alpha-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol. 1990 ; 37 (3). 375-378
8. Lepor H, Kazzazi A, Djavan B. Alpha blockers for the treatment of benign prostatic hyperplasia: the new era. Curr Opin Urol. 2012 ; 22 (1). 7-15
9. O'Brien WM. Benign prostatic hypertrophy. Am Fam Physician. 1991 ; 44 (1). 162-171
10. Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol. 2006 ; 175 (3 pt 2). S19 - S24
11. Tom WC.. Combination therapy for benign prostatic hyperplasia. Pharmacist's Letter/Prescriber's Letter. 2008 ; 24 (document 240806). 4
12. Research Triangle Park, NC: GlaxoSmithKline ; 2010 :
13. Whitehouse Station, NJ: Merck ; 2010:
14. Cardura XL New York, NY: Pfizer ; 2009:
15. North Chicago, IL: Abbott ; 2009:
16. Cardinal Health [Internet]. http://www.cardinal.com. Accessed February 9, 2011.
17. Bridgewater, NJ: Sanofi-Synthelabo ; 2009:
18. Ridgefield, CT: Boehringer Ingelheim ; 2009:
19. Corona, CA: Watson ; 2009:
20. Research Triangle, NC: GlaxoSmithKline ; 2011:
21. Red book: pharmacy's fundamental reference. Montvale, NJ: Thomson PDF ; c2010:
22. Wurzel R, Ray P, Major-Walker K, et al. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2007 ; 10 (2). 149-154 (Pubitemid 46881666)
23. McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992 ; 74 (3). 505-508
24. Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol. 2008 ; 179 (2). 616-621
25. Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder. JAMA. 2006 ; 296 (19). 2319-2328 (Pubitemid 44749359)
26. Athanasopoulos A, Gyftopoulos D, Giannitsas K, et al. Combination treatment with an α-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol. 2003 ; 169 (6). 2253-2256 (Pubitemid 36576764)
27. Wasson JH, Reda DJ, Bruskewitz RC, et al. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. N Engl J Med. 1995 ; 332 (2). 75-79
28. CunninghamGRKadmonD. Surgical and other invasive therapies of benign prostate hyperplasia [Internet]. http://www.uptodate.com/contents/surgical-and- other-invasive-therapies-of-benign-prostatic-hyperplasia. Accessed March 6, 2011.
29. Lerner LB, Tyson MD. Holmium laser applications of the prostate. Urol Clin North Am. 2009 ; 36 (4). 485-495
30. Hawary A, Mukhtar K, Sinclair A, et al. Transurethral resection of the prostate syndrome: almost gone but not forgotten. J Endourol. 2009 ; 23 (12). 2013-2020
31. Meyer JP, Gillatt DA, Lush R, et al. Managing the warfarinized urological patient. BJU Int. 2003 ; 92 (4). 351-354 (Pubitemid 37100506)
32. Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 ; 141 (2 suppl). e326S - e350S
33. Elzayat E, Habib E, Elhilali M. Holmium laser enucleation of the prostate in patients on anticoagulant therapy or with bleeding disorders. J Urol. 2006 ; 175 (4). 1428-1432
34. Forrest JB, Clemens JQ, Finamore P, et al. AUA Best Practice Statement for the prevention of deep vein thrombosis in patients undergoing urologic surgery. J Urol. 2009 ; 181 (3). 1170-1177
35. Dirksen SR Medical-Surgical Nursing: Assessment and Management of Clinical Problems. 7 th ed. St. Louis, MO: Mosby Elsevier; 2007:1414-1439. Lewis SL McLean Heitkemper M Dirksen SR Graber O'Brien PG Bucher L, ed. St. Louis, MO: Mosby Elsevier ; 2007: 1414-1439.
36. Nicolle LE. Update in adult urinary tract infection. Curr Infect Dis Rep. 2011 ; 13 (6). 552-560